Infinity Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Infinity Pharmaceuticals

INFI 0.0160

-4.8%

Sep 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (53)	7/27/2006 5:03:16 PM
From: tuck	Read Replies (1) of 210

>>You wonder if Kosan will walk away from their 17-aag, fall back to their epothilone program. Holtzman says they have a better drug, and I have to believe it, well I don't have to, but I want to. The bit about solubility rings true and sounds very plausible, to me. << Kosan might walk away from 17-AAG (though I think some of the studies are funded by NIH, so why not keep it and learn?), but probably not 17-DMAG. 17-DMAG is the 2nd generation compound, and is hydrophilic. Addresses the solubility issues that Infinity crows about solving. Couldn't tell you which is the better drug. Message 22663965 Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next